TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14729745
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg every 12 h (n = 215)
Study: 7967317
Drug: SM (streptomycin)
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM (streptomycin) twice weekly for 6 months in addition to INH and RFP for 9 months (S2 group)
Study: 21158908
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day plus Melatonin 3 mg
Study: 21158908
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day plus Melatonin 5 mg
Study: 17880560
Drug: Subcutaneous histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous histamine (1-10 ng twice a week; n = 46)
Study: 17880560
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium valproate (500 mg daily dose; n = 46)
Study: 3631681
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (dapsone and antivenom)
Study: 30680975
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (LABA-LAMA-ICS) - vilanterol 25 µg/umeclidinium 62.5 µg/fluticasone furoate 100 µg
Study: 30680975
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (LABA-ICS or LABA-LAMA)
Study: 19589164
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment for malaria (IPTp) using sulfadoxine-pyrimethamine (SP)
Study: 9576446
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg b.i.d.
Study: 26474679
Drug: Fluticasone propionate/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/formoterol 500/20 μg b.i.d.
Study: 26474679
Drug: Fluticasone propionate/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/formoterol 100/10 μg b.i.d.
Study: 21310551
Drug: Dronabinol 20mg
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol 20mg twice a day
Study: 12755528
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 50 microg every 4 h
Study: 10868559
Drug: E2/NETA 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/NETA 1 mg
Study: 3745524
Drug: Increasing concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing concentrations of anthralin (0.3%, 1%, 3%) for patients who failed to respond to UVB therapy
Study: 26954876
Drug: Oral dyclonine
Normalized name: DYCLONINE
DrugBank: Dyclonine (DB00645)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dyclonine hydrochloride mucilage (ODHM)
Study: 26954876
Drug: Tetracaine spray
Normalized name: benzocaine / butamben / tetracaine Mucosal Spray [Cetacaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine spray (TS)
Study: 25019119
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with occlusal splint and analgesic and muscle relaxant medication (Group A)
Study: 25019119
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group C) - patients who refused treatment
Study: 18508951
Drug: Midostaurin 25
Normalized name: midostaurin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin 25 mg bid
Study: 18508951
Drug: Midostaurin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin 50 mg bid
Study: 18508951
Drug: Midostaurin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin 75 mg bid
Study: 18508951
Drug: Midostaurin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin 75 mg tid
Study: 18508951
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 100 mg dose
Study: 18508951
Drug: Midostaurin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin 50 to 225 mg/day
Study: 15910012
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg before MDMA 100 mg
Study: 15910012
Drug: Placebo before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo before MDMA 100 mg
Study: 10887306
Drug: Salbutamol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (100 microgram, 2 puffs 4 times daily)
Study: 14621753
Drug: Sequential course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential course of 14 days conventional immunosuppression (ALG, azathioprine, steroids) followed by cyclosporine and steroids
Study: 14621753
Drug: Conventional immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunosuppression for 2 days followed by cyclosporine and steroids
Study: 27036555
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) lansoprazole
Study: 16082736
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment (peginterferon monotherapy for 48 weeks or shorter combination therapy for 24 weeks for RVR; triple therapy with histamine for 48 weeks or prolonged combination therapy for 72 weeks for SPR; triple therapy for FPR; high-dose peginterferon (360 microg/week) plus ribavirin for NUR)
Study: 16082736
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (peginterferon alfa-2a 180 microg/week and ribavirin 1000-1200 mg/day)
Study: 16082736
Drug: Histamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (1 mg/day) in addition to peginterferon and ribavirin
Study: 16082736
Drug: High-dose peginterferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose peginterferon (360 microg/week) plus ribavirin
Study: 7952988
Drug: Combined chlorpromazine
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined chlorpromazine (600 mg daily) and electroconvulsive therapy (ECT)
Study: 3555510
Drug: Methotrexate (MTX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (MTX), 10 mg/week, orally
Study: 3555510
Drug: Azathioprine (AZA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (AZA), 100 mg/day, orally
Study: 2294126
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human GH (hGH) at a dose of 1 IU/kg.week
Study: 2294126
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human GH (hGH) at a dose of 1 IU/kg.week + 25 ng/kg.day ethinyl estradiol (E2)
Study: 1100683
Drug: 1% chlorhexidine-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine-containing gel used once a day for 4 weeks
Study: 1100683
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel used during control period for 4 weeks
Study: 1100683
Drug: Standardized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized oral hygiene instruction for 12 subjects
Study: 31940591
Drug: In vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo Treg depletion (IVTRD) with basiliximab 20 mg IV on day +1 post-ASCT
Study: 29871195
Drug: Intratympanic gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic gentamicin (ITG), 1 ml of gentamicin sulfate (40 g/L) buffered with 0.5 ml of sodium bicarbonate, administered weekly for 2 times
Study: 29871195
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone (ITD), 5 mg for the first two days, then weekly for 4 weeks
Study: 26013113
Drug: Herbal drug
Normalized name: herbal drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal drug combination (Sinupret® extract Dragees) - daily dosage 3 × 160 mg
Study: 26013113
Drug: Herbal drug
Normalized name: herbal drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal drug combination (Sinupret® extract Dragees)
Study: 23812875
Drug: IDegSimple (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDegSimple (once-daily insulin degludec with simple titration algorithm)
Study: 23812875
Drug: IDegStep-wise (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDegStep-wise (once-daily insulin degludec with step-wise titration algorithm)
Study: 22303704
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin calcium (LMWHC) combined with Yinxing Damo Injection (YDI)
Study: 22303704
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin calcium (LMWHC)
Study: 22303704
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin calcium (LMWHC) combined with YDI
Study: 2963644
Drug: 0.02 mg
Normalized name: escin 0.02 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg (0.04 mg) controlled dosage aerosol
Study: 2963644
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg ipratropium bromide (ITB)
Study: 2963644
Drug: Intravenous doses
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous doses between 0.25 mg and 0.5 mg ITB
Study: 30224391
Drug: 8-week group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week group-based cognitive remediation therapy (CRT)
Study: 30658632
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements
Study: 24671165
Drug: A‐CHESS smartphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: A‐CHESS smartphone application (treatment as usual plus A‐CHESS)
Study: 19887503
Drug: Candesartan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (4 to 16 mg daily)
Study: 3117447
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of insulin and GRF
Study: 31420292
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone at home
Study: 31420292
Drug: Intravenous flucloxacillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous flucloxacillin in hospital
Study: 25837194
Drug: Perineural injection
Normalized name: ROPIVACAINE HYDROCHLORIDE 2 mg in 1 mL PERINEURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perineural injection (PN)
Study: 24165382
Drug: LT vaccine
Normalized name: hepatitis A adult vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT vaccine
Study: 21574174
Drug: 45 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg/day vitamin K2
Study: 21574174
Drug: 90 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg/day vitamin K2
Study: 1467095
Drug: Extradural infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extradural infusion of 0.15% bupivacaine with 0.01% diamorphine
Study: 1467095
Drug: Extradural bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural bolus diamorphine 3.6 mg
Study: 1467095
Drug: Patient-controlled i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled i.v. administration of diamorphine at a maximum rate of 1 mg per 5 min
Study: 6379507
Drug: Bovine brain
Normalized name: bovine brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine brain gangliosides, 40 mg daily intramuscular injections for 6 months
Study: 16372814
Drug: Dexamethasone-cyclophosphamide (D/C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone-cyclophosphamide (D/C) pulse therapy
Study: 16372814
Drug: Methylprednisolone-azathioprine (M/A)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methylprednisolone-azathioprine (M/A) therapy
Study: 9485967
Drug: Bupivacaine 0.0625%
Normalized name: BUPIVACAINE 0.0625%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.0625% with fentanyl 2.5 micrograms.ml‐1 at a rate of 10‐12 ml.h‐1
Study: 2166716
Drug: Soluble dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble dietary fibre supplement (7 g/day for 2 weeks)
Study: 7106067
Drug: 233 μg/m3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 233 μg/m3 sulfuric acid
Study: 7106067
Drug: 418 μg/m3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 418 μg/m3 sulfuric acid
Study: 7106067
Drug: 939 μg/m3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 939 μg/m3 sulfuric acid
Study: 26963842
Drug: Brexpiprazole 3
Normalized name: brexpiprazole 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole 3 mg/day
Study: 25206295
Drug: Probiotic combination
Normalized name: PROBIOTIC COMBINATION CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic combination (Lactobacillus acidophilus ATCC 700396 and Bifidobacterium lactis ATCC SD5220)
Study: 20397080
Drug: 6% Cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% Cellulose Sulfate microbicide gel
Study: 17917625
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of prednisolone for 6 weeks followed by topical application of 2% minoxidil for 14 weeks
Study: 17917625
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of prednisolone and minoxidil
Study: 16086923
Drug: TnT-positive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TnT-positive group (TnT > or = 0.1 ng/mL)
Study: 16086923
Drug: TnT-positive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TnT-positive group (TnT > or = 0.03 ng/mL)
Study: 16086923
Drug: TnT-positive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TnT-positive group (TnT > or = 0.01 ng/mL)
Study: 12161826
Drug: Center-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Center-based exercise (endurance, strength, balance, flexibility) 3 times weekly for months 1 to 6, once weekly for months 7 to 12 with home exercise 2 sessions a week, and at home only for months 13 to 18
Study: 10444056
Drug: 0.3% topical
Normalized name: ZORYVE 0.3% Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% topical ciprofloxacin presoaked in disposable soft contact lenses for 10-12 hours, applied for 3 hours (Group A)
Study: 10444056
Drug: 0.3% topical
Normalized name: ZORYVE 0.3% Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% topical ciprofloxacin presoaked in disposable soft contact lenses for 10-12 hours, applied for 5-6 hours (Group B)
Study: 10444056
Drug: 0.3% topical
Normalized name: ZORYVE 0.3% Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% topical ciprofloxacin presoaked in disposable soft contact lenses for 10-12 hours, applied for 8-12 hours (Group C)
Study: 2399774
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and chemotherapy (combination of bleomycin, vincristine, mitomycin-C, and cisplatin; later carboplatin and bleomycin)
Study: 7365120
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of brain wave stimulator and concentration exercise
Study: 25997818
Drug: Ganetespib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganetespib (150 mg/m² on days 1 and 15) in combination with Docetaxel (75 mg/m² on day 1)
Study: 25997818
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m² on day 1) alone
Study: 23245197
Drug: Contingency Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency Management (CM) treatment
Study: 15552197
Drug: Topical NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical NSAIDs for three days preoperatively
Study: 9609411
Drug: ATIII (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATIII (total dose 24000 units)
Study: 367043
Drug: Clonidine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.05 mg twice daily
Study: 367043
Drug: Tyramine 125
Normalized name: tyramine
DrugBank: Tyramine (DB08841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyramine 125 mg
Study: 30783069
Drug: Internet-based Cognitive-Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based Cognitive-Behavioural Therapy (iCBT), 8-week therapist-guided
Study: 26446153
Drug: Interactive training
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive training sessions for nursing staff (two 4-hour sessions) to recognize potentially harmful medications
Study: 21826782
Drug: Transfusions and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusions and chelation (standard therapy)
Study: 17229772
Drug: Venlafaxine 37.5
Normalized name: venlafaxine 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 37.5 mg twice a day for 4 weeks
Study: 17229772
Drug: Clonidine 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.075 mg twice a day for 4 weeks
Study: 7930697
Drug: RT-PCR assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT-PCR assay for MCV RNA on PBMC RNA preparations
Study: 30418116
Drug: Medical Cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Cannabis Therapy (MCT) after 3 months of Standardised Analgesic Therapy (SAT)
Study: 30418116
Drug: Medical Cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Cannabis Therapy (MCT)
Study: 30418116
Drug: Standardised Analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised Analgesic Therapy (SAT)
Study: 25968836
Drug: Intravaginal DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal DHEA (6.5 mg daily for 52 weeks)
Study: 19779467
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1,500 mg per day)
Study: 16540815
Drug: quetiapine (400‐600
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine (400‐600 mg/day)
Study: 16540815
Drug: divalproex (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: divalproex (serum level 80‐120 microg/mL)
Study: 3936908
Drug: Oral L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-carnitine supplementation (70 mumol/l/kg/24 h in 24 mL of 5% dextrose) for seven days
Study: 3936908
Drug: Placebo supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplementation (dextrose 5%, 24 cc/24 h) for seven days
Study: 31079938
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg plus bevacizumab 15 mg/kg intravenously once every 3 weeks
Study: 31079938
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg orally once daily for 4 weeks on, 2 weeks off
Study: 25122645
Drug: 0.25, 0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25, 0.5, and 1.0 L of milk
Study: 22425473
Drug: Standard social
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard social cognitive rehabilitation treatment, n=24
Study: 12456597
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or no treatment (Control)
Study: 8324872
Drug: Epirubicin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 75 mg/m2
Study: 8648369
Drug: Epirubicin 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 90 mg/m2
Study: 8612318
Drug: Epirubicin 105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 105 mg/m2
Study: 8324872
Drug: Epirubicin 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 120 mg/m2
Study: 2007742
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Beclomethasone dipropionate (BD) enemas for 28 days
Study: 2007742
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Betamethasone phosphate (BP) enemas for 28 days
Study: 6347921
Drug: Sulconazole nitrate
Normalized name: Sulconazole Nitrate
DrugBank: Sulconazole (DB06820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulconazole nitrate cream 1%
Study: 6347921
Drug: Miconazole nitrate
Normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole nitrate cream 2% (twice daily application)
Study: 6347921
Drug: Sulconazole nitrate
Normalized name: Sulconazole Nitrate
DrugBank: Sulconazole (DB06820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulconazole nitrate cream 1% (bid)
Study: 31331390
Drug: Past H.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Past H. pylori infection (sero-negative to H. pylori IgG antibody) with atrophic gastritis
Study: 22943685
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of mesenchymal stem cells (MSCs) [(4.9 ± 1.7) × 10(8), n = 17]
Study: 22943685
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of mononuclear stem cells (MNCs) [(5.1 ± 2.0) × 10(8), n = 16]
Study: 18978490
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg daily for 3 weeks, then 10 mg daily for 3 weeks
Study: 11588522
Drug: nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitrendipine (20 mg/d)
Study: 11588522
Drug: trandolapril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: trandolapril (2 mg/d)
Study: 2574764
Drug: Tiludronate 100
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiludronate 100 mg daily for 6 months
Study: 29588137
Drug: Calcitriol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.25 mg per day)